[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nThe patient presents with:\n- Progressive sleep dysfunction over 2 years\n- Dream enactment (REM sleep behavior disorder)\n- Nocturnal stridor\n- Daytime somnolence\n- Gait instability\n- Mild cognitive decline\n- Polysomnography showing non-REM parasomnias AND REM sleep behavior disorder\n- Normal CSF\n- Mild cerebellar atrophy on MRI\n\nThis combination of features is highly characteristic of Anti-IgLON5 disease. Key features that point to this diagnosis:\n\n1. Sleep disorder with both REM and non-REM parasomnias - This is a hallmark of anti-IgLON5 disease\n2. Nocturnal stridor - Very characteristic of anti-IgLON5 disease due to brainstem involvement\n3. Gait instability with cerebellar atrophy - Common in anti-IgLON5 disease\n4. Cognitive decline - Part of the syndrome\n5. Normal CSF - Anti-IgLON5 disease often has normal or near-normal CSF (unlike many other autoimmune encephalitides)\n6. Chronic progressive course - Typical for anti-IgLON5 disease\n\nLet me consider the other options:\n- Anti-Hu: Associated with sensory neuronopathy, limbic encephalitis, cerebellar degeneration, but not this specific sleep phenotype\n- Anti-Yo: Primarily causes cerebellar degeneration in women with gynecological cancers\n- Anti-Ma2: Associated with limbic encephalitis, hypothalamic dysfunction, and brainstem involvement, but the sleep phenotype here is more specific for IgLON5\n- Anti-NMDA receptor: Causes a distinct syndrome with psychiatric symptoms, seizures, movement disorders, and autonomic instability, typically in younger patients\n\nThe combination of complex sleep disorder (both REM and non-REM abnormalities), stridor, gait problems, and cognitive decline with relatively normal CSF is pathognomonic for anti-IgLON5 disease.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nKey clinical features:\n- 32-year-old woman\n- Irregular vaginal bleeding 18 months after term delivery\n- Mildly elevated serum hCG (150 mIU/mL) - relatively low\n- 4 cm intrauterine mass\n- Histology: sheets of intermediate trophoblastic cells with eosinophilic cytoplasm\n- Low mitotic index\n- IHC: strongly positive for hPL, negative for hCG\n\nLet me consider each option:\n\nA) Choriocarcinoma: Characterized by biphasic pattern of cytotrophoblast and syncytiotrophoblast, high mitotic activity, extensive hemorrhage and necrosis, and typically very high hCG levels. This doesn't match.\n\nB) Placental site trophoblastic tumor (PSTT): Arises from intermediate trophoblast at the implantation site. Features include:\n- Sheets of intermediate trophoblastic cells\n- Eosinophilic/amphophilic cytoplasm\n- Low mitotic index\n- Strongly positive for hPL (human placental lactogen)\n- Weakly positive or negative for hCG\n- Relatively low serum hCG levels\n- Can occur months to years after any pregnancy (including term delivery)\n\nC) Epithelioid trophoblastic tumor (ETT): Also from intermediate trophoblast but from chorionic-type. Typically positive for p63, inhibin, and has different morphology with more epithelioid nests.\n\nD) Persistent hydatidiform mole: Would show hydropic villi and trophoblastic proliferation, typically occurs within months of molar pregnancy.\n\nE) Invasive mole: Requires prior molar pregnancy and shows invasion of myometrium by hydropic villi.\n\nThe combination of:\n- Intermediate trophoblastic cells\n- Low mitotic index\n- Strong hPL positivity\n- Negative hCG staining\n- Low serum hCG\n- Following term pregnancy\n\nThis is classic for Placental Site Trophoblastic Tumor (PSTT).\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Let me analyze this case systematically.\n\nThis 18-year-old male has Danon disease (LAMP2 mutation) with:\n- Severe hypertrophic cardiomyopathy (septal thickness 28 mm)\n- WPW pattern (ventricular pre-excitation)\n- Multiple accessory pathways (3 identified)\n- Recurrent syncope\n- Pre-excited atrial fibrillation despite maximal medical therapy\n\nKey considerations:\n\nDanon disease is an X-linked lysosomal storage disorder causing severe HCM, typically with rapid progression in males. It's associated with multiple accessory pathways (often posteroseptal) and has a poor prognosis - males often require heart transplantation by their 20s.\n\nPre-excited atrial fibrillation is dangerous because rapid conduction through accessory pathways can lead to ventricular fibrillation and sudden death.\n\nLet me evaluate each option:\n\nA) Flecainide - Contraindicated in structural heart disease (severe HCM). Also, in pre-excited AF, AV nodal blocking agents should be avoided, and while flecainide can slow accessory pathway conduction, it's not appropriate here given the structural heart disease.\n\nB) Catheter ablation - While typically first-line for WPW with symptomatic arrhythmias, in Danon disease, multiple accessory pathways are common and often recur after ablation. The success rate is lower, and new pathways can develop. Additionally, with severe HCM and ongoing symptoms, this may not address the underlying progressive cardiomyopathy.\n\nC) Increase beta-blocker - Already on maximal medical therapy, and beta-blockers alone won't prevent rapid conduction through accessory pathways in AF.\n\nD) Heart transplantation evaluation - Given Danon disease in a male with severe HCM (28mm septum), recurrent syncope (suggesting high arrhythmic risk), multiple accessory pathways, and refractory symptoms despite maximal therapy, transplant evaluation is appropriate. Danon disease in males has rapid progression, and transplantation is often the definitive treatment.\n\nE) Dual-chamber pacemaker - Does not address the arrhythmia risk or underlying disease.\n\nGiven the severity of disease, the progressive nature of Danon cardiomyopathy in males, multiple accessory pathways (which are difficult to ablate and tend to recur in Danon disease), and refractory symptoms, heart transplantation evaluation is the most appropriate next step.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-004", "question": "A 42-year-old woman with multiple sclerosis on natalizumab for 30 months develops subacute cognitive decline over 3 weeks. Her JCV antibody index is 2.8. Brain MRI reveals new non-enhancing subcortical white matter lesions without mass effect. CSF JCV PCR is positive. Which intervention is most critical to improve survival?", "options": ["A) Continue natalizumab with close monitoring", "B) Switch directly to ocrelizumab", "C) Initiate immediate plasma exchange", "D) Start mirtazapine 30 mg daily", "E) Begin mefloquine 250 mg weekly"], "answer": "C", "answer_index": 2, "explanation": "Natalizumab-associated progressive multifocal leukoencephalopathy requires immediate drug discontinuation and plasma exchange to rapidly clear the monoclonal antibody, preventing immune reconstitution inflammatory syndrome (IRIS) and improving survival. Continuing or switching immunosuppression is contraindicated. Mirtazapine and mefloquine have been investigated but lack evidence of benefit. Plasma exchange is the only intervention shown to alter mortality.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nThis 42-year-old woman with MS on natalizumab for 30 months presents with:\n- Subacute cognitive decline over 3 weeks\n- High JCV antibody index (2.8 - elevated, indicating higher PML risk)\n- New non-enhancing subcortical white matter lesions\n- Positive CSF JCV PCR\n\nThis clinical picture is classic for Progressive Multifocal Leukoencephalopathy (PML), a serious complication of natalizumab therapy.\n\nLet me evaluate each option:\n\nA) Continue natalizumab with close monitoring - This would be inappropriate as natalizumab is causing the immunosuppression leading to PML.\n\nB) Switch directly to ocrelizumab - This would continue immunosuppression with another agent, which is contraindicated in active PML.\n\nC) Initiate immediate plasma exchange - This is the critical intervention. Plasma exchange (plasmapheresis) rapidly removes natalizumab from circulation, allowing immune reconstitution. This is the standard of care for natalizumab-associated PML to restore immune function and allow the body to fight JCV.\n\nD) Start mirtazapine 30 mg daily - Mirtazapine has been studied as an adjunctive therapy for PML due to its potential to block 5-HT2A receptors (which JCV may use for cell entry), but evidence is limited and it's not the most critical intervention.\n\nE) Begin mefloquine 250 mg weekly - Mefloquine was investigated for anti-JCV activity but clinical trials have not shown significant benefit.\n\nThe most critical intervention for survival in natalizumab-associated PML is immediate plasma exchange (PLEX) to rapidly clear the drug and restore immune surveillance. This allows the immune system to mount a response against JCV, which is essential for survival.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-005", "question": "A 58-year-old man presents with a 5-year history of chronic urticarial rash, recurrent fevers, debilitating bone pain, and monoclonal IgM kappa on serum protein electrophoresis. Symptoms are refractory to high-dose H1/H2 antihistamines. Laboratory studies reveal markedly elevated ESR and CRP. Which cytokine is the primary therapeutic target for this condition?", "options": ["A) Interleukin-1", "B) Interleukin-6", "C) Interleukin-17", "D) Tumor necrosis factor-alpha", "E) Interferon-gamma"], "answer": "A", "answer_index": 0, "explanation": "Schnitzler syndrome is an autoinflammatory disease driven by NLRP3 inflammasome activation with overproduction of IL-1β. Anakinra, an IL-1 receptor antagonist, is first-line therapy and induces rapid remission. While IL-6 and TNF-alpha may be elevated, they are not the primary pathogenic cytokines. IL-17 and interferon-gamma are not central to the disease mechanism.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nThe patient presents with:\n- Chronic urticarial rash (5 years)\n- Recurrent fevers\n- Debilitating bone pain\n- Monoclonal IgM kappa gammopathy\n- Refractory to antihistamines\n- Elevated inflammatory markers (ESR, CRP)\n\nThis clinical presentation is classic for Schnitzler syndrome, a rare autoinflammatory disorder characterized by:\n- Chronic urticaria (non-pruritic, neutrophilic)\n- Monoclonal gammopathy (usually IgM)\n- Systemic inflammation (fever, elevated acute phase reactants)\n- Bone pain/abnormalities\n- Poor response to antihistamines\n\nSchnitzler syndrome is considered an acquired autoinflammatory disease with dysregulation of the innate immune system. The pathophysiology involves excessive interleukin-1 (IL-1) signaling.\n\nTreatment with IL-1 inhibitors (anakinra, canakinumab, rilonacept) has shown dramatic and rapid efficacy in Schnitzler syndrome, often with complete resolution of symptoms within days. This response to IL-1 blockade confirms IL-1 as the primary driver of the disease.\n\nWhile IL-6 is also elevated in inflammatory conditions and TNF-alpha blockers have been tried, they are not as effective as IL-1 inhibitors in Schnitzler syndrome. The remarkable response to IL-1 targeting therapy makes it the primary therapeutic target.\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-006", "question": "A 35-year-old man with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, and cerebellar ataxia is diagnosed with cerebrotendinous xanthomatosis. Serum cholestanol level is markedly elevated. Which treatment modality has been shown to halt neurologic progression in this disorder?", "options": ["A) High-intensity statin therapy", "B) Chenodeoxycholic acid supplementation", "C) Weekly LDL apheresis", "D) Ezetimibe monotherapy", "E) Coenzyme Q10 supplementation"], "answer": "B", "answer_index": 1, "explanation": "Cerebrotendinous xanthomatosis results from CYP27A1 deficiency, causing cholestanol accumulation in neural tissue. Chenodeoxycholic acid inhibits cholesterol 7α-hydroxylase, reducing cholestanol synthesis and stabilizing neurologic function. Statins, ezetimibe, and LDL apheresis do not effectively lower central nervous system cholestanol. Coenzyme Q10 is used for mitochondrial disorders, not this condition.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case of cerebrotendinous xanthomatosis (CTX).\n\nCTX is a rare autosomal recessive lipid storage disease caused by mutations in the CYP27A1 gene, which encodes sterol 27-hydroxylase. This enzyme is crucial for bile acid synthesis. The deficiency leads to:\n- Reduced chenodeoxycholic acid (CDCA) production\n- Accumulation of cholestanol and bile alcohols\n- Deposition in various tissues including tendons, brain, and eyes\n\nClinical features include:\n- Bilateral cataracts (often juvenile onset)\n- Tendon xanthomas (especially Achilles)\n- Progressive neurological dysfunction (ataxia, dementia, peripheral neuropathy)\n- Elevated serum cholestanol\n\nTreatment rationale:\n- Chenodeoxycholic acid (CDCA) supplementation is the treatment of choice\n- CDCA works by suppressing the abnormal bile acid synthesis pathway through negative feedback\n- This reduces cholestanol and bile alcohol production\n- Early treatment can prevent neurological progression and may even reverse some symptoms\n- It normalizes cholestanol levels\n\nLet me evaluate the other options:\n- A) Statins: May be used adjunctively but don't address the underlying defect\n- C) LDL apheresis: Not indicated as this isn't primarily an LDL problem\n- D) Ezetimibe: May help reduce cholesterol absorption but doesn't treat the core defect\n- E) Coenzyme Q10: Not a primary treatment for CTX\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-007", "question": "A 16-year-old girl presents with cyclic, worsening right pelvic pain for 6 months, occurring with each menses. She reports normal menstrual bleeding. Pelvic ultrasound reveals a didelphic uterus with a 5 cm right hematocolpos and a normal left uterine horn. Renal ultrasound demonstrates absence of the right kidney. Which congenital anomaly best explains this presentation?", "options": ["A) Mayer-Rokitansky-Küster-Hauser syndrome", "B) OHVIRA syndrome", "C) Complete androgen insensitivity syndrome", "D) Transverse vaginal septum", "E) Imperforate hymen"], "answer": "B", "answer_index": 1, "explanation": "OHVIRA (Obstructed Hemivagina with Ipsilateral Renal Agenesis) syndrome is characterized by a didelphic uterus with obstructed hemivagina causing hematocolpos and ipsilateral renal agenesis. Patients have normal menses from the patent uterine horn. MRKH syndrome involves uterine agenesis. CAIS affects 46,XY individuals. Transverse vaginal septum and imperforate hymen occur with a normal uterus and kidneys.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nKey findings:\n- 16-year-old girl with cyclic pelvic pain during menses for 6 months\n- Normal menstrual bleeding (indicating at least one functioning outflow tract)\n- Didelphic uterus (two separate uteri)\n- 5 cm right hematocolpos (blood accumulation in vagina on right side)\n- Absent right kidney (unilateral renal agenesis)\n\nAnalysis of options:\n\nA) Mayer-Rokitansky-Küster-Hauser syndrome: This involves absence of the uterus and upper vagina with normal ovaries. The patient has a uterus, so this doesn't fit.\n\nB) OHVIRA syndrome: This stands for Obstructed Hemivagina and Ipsilateral Renal Anomaly (also known as Herlyn-Werner-Wunderlich syndrome). It classically presents with:\n- Uterine didelphys\n- Obstructed hemivagina (causing hematocolpos)\n- Ipsilateral renal agenesis\n- Normal menses from the non-obstructed side\n- Cyclic pain from the obstructed side\n\nThis matches perfectly with the presentation.\n\nC) Complete androgen insensitivity syndrome: This occurs in 46,XY individuals with female external genitalia, absent uterus, and blind-ending vagina. Doesn't fit.\n\nD) Transverse vaginal septum: This would cause complete obstruction with no menstrual flow. The patient has normal menstrual bleeding, so this doesn't explain the findings.\n\nE) Imperforate hymen: This would cause complete obstruction of menstrual flow, not partial obstruction with normal menses from one side.\n\nThe combination of didelphic uterus, unilateral hematocolpos, normal menses, and ipsilateral renal agenesis is the classic triad of OHVIRA syndrome.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-008", "question": "A 62-year-old man with a HeartMate 3 left ventricular assist device presents with acute onset of dark urine, fatigue, and dizziness. Laboratory studies demonstrate LDH 2,800 U/L and plasma free hemoglobin 80 mg/dL. Device interrogation shows increased power consumption with intermittent spikes. Transthoracic echocardiography suggests inflow cannula obstruction. What is the most appropriate immediate management?", "options": ["A) Increase warfarin target INR to 3.5-4.0", "B) Initiate intravenous unfractionated heparin infusion", "C) Administer intraventricular alteplase 25 mg", "D) Deliver intrapump alteplase 10 mg via percutaneous catheter", "E) Proceed to emergent surgical pump exchange"], "answer": "D", "answer_index": 3, "explanation": "HeartMate 3 pump thrombosis is managed with low-dose intrapump alteplase (10 mg) delivered via percutaneous catheter directly into the device, which has shown high success rates. Systemic thrombolysis or intraventricular administration risks hemorrhagic stroke. Increasing anticoagulation is insufficient for established thrombosis. Surgical exchange is reserved for thrombolysis failure or hemodynamic collapse.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- 62-year-old man with HeartMate 3 LVAD\n- Acute dark urine, fatigue, dizziness\n- LDH 2,800 U/L (markedly elevated)\n- Plasma free hemoglobin 80 mg/dL (elevated)\n- Device: increased power consumption with intermittent spikes\n- Echo: inflow cannula obstruction\n\nDiagnosis:\nThis presentation is classic for pump thrombosis with hemolysis:\n- Elevated LDH and plasma free hemoglobin indicate intravascular hemolysis\n- Power spikes suggest the pump is working harder against resistance (thrombus)\n- Inflow cannula obstruction on echo confirms thrombus location\n\nManagement Options Analysis:\n\nA) Increase warfarin INR to 3.5-4.0 - This is too slow for acute pump thrombosis and won't dissolve existing clot\n\nB) IV unfractionated heparin - This prevents further clot formation but won't lyse existing thrombus causing acute obstruction\n\nC) Intraventricular alteplase 25 mg - This is not a standard approach and the dose/route is unusual\n\nD) Intrapump alteplase 10 mg via percutaneous catheter - This is not a standard technique for HeartMate devices\n\nE) Emergent surgical pump exchange - This is definitive treatment for pump thrombosis when medical management fails or in severe cases\n\nKey Considerations:\nFor HeartMate 3 pump thrombosis, the initial management typically involves:\n1. IV heparin anticoagulation intensification\n2. If hemodynamically unstable or refractory: surgical pump exchange\n\nGiven this is an acute presentation with evidence of significant hemolysis and inflow cannula obstruction, the patient needs immediate anticoagulation to prevent further thrombus propagation. While surgical exchange may ultimately be needed, IV heparin is the appropriate immediate first-line management to stabilize the patient and potentially allow for thrombus resolution before committing to surgery.\n\nHowever, if the patient is hemodynamically compromised with confirmed pump thrombosis not responding to medical therapy, surgical exchange becomes necessary.\n\nGiven the acute presentation with significant hemolysis and obstruction, IV heparin is the immediate first step before considering surgical intervention.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "Let me analyze this case systematically.\n\nKey clinical features:\n- 55-year-old immunocompetent patient\n- Gardener (occupational exposure)\n- Subacute onset (3 weeks)\n- Severe headaches, focal seizures, left hemiparesis\n- Multiple ring-enhancing lesions with surrounding edema on MRI\n- CSF: lymphocytic pleocytosis (120 cells/μL)\n- Negative bacterial, fungal, and mycobacterial cultures\n\nDifferential diagnosis considerations:\n\nThe occupation as a gardener is a crucial clue. Gardeners are exposed to soil and plant material, putting them at risk for certain infections.\n\nRing-enhancing lesions with lymphocytic pleocytosis in a gardener:\n\n1. Nocardia - Common in gardeners/soil exposure, causes brain abscesses, but typically in immunocompromised patients\n2. Sporothrix schenckii - Gardener's disease, but CNS involvement is rare\n3. Dematiaceous fungi (causing cerebral phaeohyphomycosis) - Soil exposure, can cause brain abscesses in immunocompetent individuals\n4. Cladophialophora bantiana - A dematiaceous (melanized) fungus that has neurotropism and can cause brain abscesses even in immunocompetent hosts\n\nGiven:\n- Immunocompetent host\n- Gardener (soil/plant exposure)\n- Multiple ring-enhancing lesions\n- Negative routine cultures (dematiaceous fungi may not grow on standard fungal cultures or take longer)\n\nCerebral phaeohyphomycosis (caused by dematiaceous molds like Cladophialophora bantiana) is a strong consideration. These fungi have a predilection for the CNS even in immunocompetent individuals.\n\nTreatment options:\n- Voriconazole is the drug of choice for cerebral phaeohyphomycosis/dematiaceous mold infections\n- Liposomal amphotericin B is used for various fungal infections but voriconazole has better CNS penetration and activity against these molds\n- Albendazole plus miltefosine is for free-living amoeba (Balamuthia, Acanthamoeba)\n- Vancomycin/ceftriaxone/dexamethasone is for bacterial meningitis\n- Ganciclovir/foscarnet is for CMV\n\nThe answer is E"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This case describes a classic presentation of Deficiency of Adenosine Deaminase 2 (DADA2), which is confirmed by the genetic testing showing biallelic loss-of-function mutations in ADA2.\n\nKey clinical features of DADA2 include:\n- Recurrent fevers\n- Livedo racemosa\n- Early-onset lacunar strokes\n- Vasculitic neuropathy\n- Immunodeficiency (often with low IgM)\n\nThe pathophysiology of DADA2 involves dysregulated TNF-α signaling, leading to vasculopathy and inflammation.\n\nLet me evaluate the treatment options:\n\nA) High-dose glucocorticoids - While they may provide temporary relief, they are not the most effective long-term treatment and don't address the underlying pathophysiology.\n\nB) Intravenous cyclophosphamide - This is used for various vasculitides but is not the treatment of choice for DADA2.\n\nC) Etanercept - This is a TNF-α inhibitor (soluble TNF receptor fusion protein). TNF inhibitors have been shown to be highly effective in DADA2, dramatically reducing stroke risk and controlling vasculitic manifestations.\n\nD) Anakinra - This is an IL-1 receptor antagonist, used in conditions like systemic JIA and other autoinflammatory conditions, but not the primary treatment for DADA2.\n\nE) Rituximab - This is an anti-CD20 antibody that depletes B cells. While it may help with some immunological aspects, it's not the treatment of choice for DADA2.\n\nThe standard of care for DADA2 is anti-TNF therapy, with etanercept being the most commonly used and most effective biologic for preventing strokes and controlling the vasculopathy. Multiple case series and studies have demonstrated the remarkable efficacy of TNF inhibitors in this condition.\n\nThe answer is (C)"}]